High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia

BMC Res Notes. 2022 Dec 12;15(1):369. doi: 10.1186/s13104-022-06260-4.

Abstract

Objective: Thyroid cancer incidence has steadily increased in Indonesia. However, data on Kirsten rat sarcoma virus (KRAS) and EGFR mutations in thyroid cancer in Indonesia remain unavailable, except for BRAF-V600E, the most common BRAF gene mutation. This study aimed to analyze KRAS and EGFR mutation profiles in BRAF-V600E negative thyroid cancer samples.

Results: BRAF-V600E mutations were found in papillary thyroid carcinomas in 40.3% patients with mean age of 53 years old. In BRAF-V600E-negative samples, 41.3% had KRAS mutations with mean age of 55.5 years old. KRAS mutation was found in 52.6% of follicular carcinomas and 47.4% of papillary thyroid carcinomas. Additionally, 45.7% had EGFR mutations in patients with mean age of 50.5 years old. EGFR mutation was found in 71.4% of papillary thyroid carcinoma and 28.6% of follicular carcinoma. Nearly half of the BRAF-V600E negative thyroid carcinoma samples harbored either KRAS or EGFR mutations. This finding suggests that in BRAF-V600E negative thyroid carcinoma samples, testing for RAS and EGFR mutation may be warranted for further therapeutic consideration.

Keywords: BRAF; EGFR; Indonesia; KRAS; Thyroid cancer.

MeSH terms

  • Adenocarcinoma, Follicular* / genetics
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Humans
  • Mutation
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Thyroid Cancer, Papillary / genetics
  • Thyroid Neoplasms* / genetics
  • Thyroid Neoplasms* / pathology

Substances

  • Proto-Oncogene Proteins B-raf
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
  • BRAF protein, human
  • EGFR protein, human
  • ErbB Receptors